The DEAD-box helicase DDX17 is a conserved RNA-binding protein involved in multiple aspects of RNA metabolism, including transcription, splicing, ribosome biogenesis, and miRNA processing. It plays critical roles in cellular processes such as cell cycle regulation, antiviral responses, and maintaining genomic stability. DDX17 antibodies are essential tools for studying its expression, localization, and molecular interactions in these pathways.
These antibodies are commonly used in techniques like Western blotting, immunoprecipitation (IP), and immunofluorescence (IF) to detect DDX17 in various biological samples. Due to DDX17's homology with other DEAD-box proteins (e.g., DDX5), antibody specificity is rigorously validated using knockout cell lines or siRNA-mediated knockdown to minimize cross-reactivity. Research applications focus on its role in cancer (e.g., acting as a tumor suppressor or promoter in context-dependent manner), neurodegeneration, and viral infection responses.
Commercial DDX17 antibodies are typically raised against specific epitopes within its N-terminal or C-terminal regions, often in hosts like rabbits or mice. Recent studies also highlight DDX17's phase separation activity and involvement in liquid-liquid phase separation (LLPS), driving the formation of membraneless organelles. Validated antibodies aid in exploring these emerging mechanisms, making them vital for dissecting DDX17's dual roles in RNA homeostasis and disease pathogenesis.